↑ 疾患リストへ ← 戻る

 260. シトステロール血症 [臨床試験数:12,薬物数:11(DrugBank:4),標的遺伝子数:1,標的パスウェイ数:1] 

Searched query = "Sitosterolemia"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01948648February 6, 201819 November 2018Effects of Fish Oil and ColesevelamEffects of Fish Oil, Colesevelam and Combination Therapy on Sterol Metabolism in SitosterolemiaSitosterolemiaDrug: Colesevelam;Dietary Supplement: Fish Oil;Drug: Combination of fish oil and colesevelamUniversity of ManitobaRecruiting8 YearsN/AAll16N/ACanada
2NCT01584206April 201211 April 2016Sitosterolemia MetabolismAssessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With EzetimibeSitosterolemiaDrug: EzetimibeUniversity of ManitobaNot recruiting16 Years99 YearsBoth8N/ACanada
3NCT00531128September 10, 200711 June 2018The Effect of Dietary Sitosterol on Blood Sugar and CholesterolA Nutrigenomics Intervention for the Study of the Role of Dietary Sitosterol on Lipid, Glucose and Energy MetabolismSitosterolemiaBehavioral: High/Low SitosterolNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not recruiting18 YearsN/AAll14N/AUnited States
4NCT00704444June 20079 March 2015A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244)Designated Drug Use Investigation (12 Weeks) of Zetia 10mg Tablets - A 12-Week Designated Drug Use Investigation of Zetia Monotherapy and Combination TherapyHypercholesterolemia;Familial Hypercholesterolemia;Homozygous SitosterolemiaDrug: Ezetimibe;Drug: Ezetimibe + other lipid-lowering medication(s)Merck Sharp & Dohme Corp.BayerNot recruitingN/AN/ABoth11332N/A
5NCT00705211June 20079 March 2015A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)Designated Drug Use Investigation (Long-Term Administration) of Zetia 10-mg Tablets - A 52-Week Long-Term Designated Drug Use Investigation of Zetia Monotherapy and Combination TherapyHypercholesterolemia;Familial Hypercholesterolemia;Homozygous SitosterolemiaDrug: Ezetimibe;Drug: Ezetimibe + other lipid-lowering medication(s)Merck Sharp & Dohme Corp.BayerNot recruitingN/AN/ABoth1794N/A
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2004-001580-22-DE21/12/200410 February 2014A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose StudyA Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose StudyHomozygous SitosterolemiaTrade Name: Ezetrol
Product Name: Ezetrol
Product Code: MK-0653
Pharmaceutical Form: Tablet
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10, 40-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
MSD SHARP & DOHME GMBHNot RecruitingFemale: yes
Male: yes
30Germany;United Kingdom
7NCT00099996December 200419 February 2015Higher-Dose Ezetimibe to Treat Homozygous SitosterolemiaA Study to Assess Adding Ezetimibe 30 mg to Ongoing Treatment With Ezetimibe 10 mg in Patients With Homozygous SitosterolemiaHeart Diseases;Metabolism, Inborn ErrorsDrug: SCH-58235;Drug: EzetimibeNational Heart, Lung, and Blood Institute (NHLBI)Not recruitingN/AN/ABoth3Phase 3United States
8NCT00092898October 200416 December 2017An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to An Ongoing Regimen of Ezetimibe 10 mg in Patients Homozygous SitosterolemiaLipid Metabolism, Inborn Errors;Heart DiseaseDrug: MK0653, ezetimibe;Drug: Comparator: placeboMerck Sharp & Dohme Corp.Not recruiting18 Years85 YearsAll30Phase 3United States
9NCT00092833July 200216 December 2017Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous SitosterolemiaHypercholesterolemia, Familial;Lipid Metabolism, Inborn ErrorsDrug: Comparator: ezetimibeMerck Sharp & Dohme Corp.Not recruiting8 YearsN/AAll49Phase 3United States
10NCT00045812March 200119 February 2015SCH-58235 (Ezetimibe) to Treat Homozygous SitosterolemiaA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate SCH-58235 in Homozygous SitosterolemiaLipoidosisDrug: SCH-58235National Heart, Lung, and Blood Institute (NHLBI)Not recruitingN/AN/ABoth5Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00092807February 12, 200116 December 2017Sitosterolemia Extension Study (0653-003)(COMPLETED)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label ExtensionLipid Metabolism, Inborn Errors;Heart DiseaseDrug: MK0653, ezetimibe;Drug: Comparator: placeboMerck Sharp & Dohme Corp.Not recruiting10 YearsN/AAll37Phase 3United States
12NCT00092820February 12, 200116 December 2017Sitosterolemia Extension Study (0653-004)(COMPLETED)A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous SitosterolemiaLipid Metabolism, Inborn Errors;Heart DiseaseDrug: MK0653, ezetimibe;Drug: Comparator: placeboMerck Sharp & Dohme Corp.Not recruiting10 YearsN/AAll58Phase 3

先頭へ